Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 61, Issue 1, 2012, Pages 22-29

  Zoppini, Giacomo ^a   Negri, Carlo ^a   Stoico, Vincenzo ^a   Casati, Stefano ^b   Pichiri, Isabella ^a   Bonora, Enzo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ALBUMINURIA; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CONFERENCE PAPER; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RETINOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 82955213026     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2011.05.004     Document Type: Conference Paper

References (29)

1. Q. Mohamed, M. Gillies, and T.Y. Wong Management of diabetic retinopathy: a systematic review JAMA 298 2007 902 916 (Pubitemid 47311296)
2. P. Rossing Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005 Diabetologia 49 2006 11 19 (Pubitemid 43151607)
3. L.S. Dalrymple, and G.A. Kaysen The effects of lipoproteins on the development and progression of renal disease Am J Nephrol 28 2008 723 731
4. R. Klein, B.E. Klein, and S.E. Moss The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more Arch Ophthalmol 107 1989 244 249 (Pubitemid 19055345)
5. E.Y. Chew, M.L. Klein, and F.L. Ferris III Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) report 22 Arch Ophthalmol 114 1996 1079 1084
6. H. Keen, E.T. Lee, and D. Russell The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes Diabetologia 44 Suppl 2 2001 S22 S30
7. L.A. Leiter The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diab Res Clin Pract 68 Suppl 2 2005 S3 14
8. A. Gupta, V. Gupta, and S. Thapar Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema Am J Ophthalmol 137 2004 675 682 (Pubitemid 38446682)
9. S. Sandhu, N. Wiebe, L.F. Fried, and M. Tonelli Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 2006 2006 2016 (Pubitemid 44036185)
10. G.F. Strippoli, S.D. Navaneethan, and D.W. Johnson Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 2008 645 651 (Pubitemid 351481234)
11. J.C. Ansquer, C. Foucher, and P. Aubonnet Fibrates and microvascular complications in diabetes-insight from the FIELD study Curr Pharm Des 15 2009 537 552
12. P. Kempler, S. Tesfaye, and N. Chaturvedi Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study Diabet Med 19 2002 900 909 (Pubitemid 35356915)
13. R. de Marco, F. Locatelli, and G. Zoppini Cause-specific mortality in type 2 diabetes Diabetes Care 22 1999 756 761
14. M. Dobiásová, and J. Frohlich The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma Clin Biochem 34 2001 583 588 (Pubitemid 34014853)
15. L.A. Stevens, J. Coresh, and T. Greene Assessing kidney function-measured and estimated glomerular filtration rate N Engl J Med 354 2006 2473 2483 (Pubitemid 43855050)
16. No authors listed Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group Ophthalmology 98 1991 786 806
17. G. Zoppini, G. Verlato, and G. Targher Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr Metab Cardiovasc Dis 19 2009 334 339
18. J.M. Gaziano, C.H. Hennekens, and C.J. O'Donnell Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction Circulation 96 1997 2520 2525 (Pubitemid 27451340)
19. H. Drexel, S. Aczel, and T. Marte Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28 2005 101 107 (Pubitemid 40095790)
20. V. Bittner, B.D. Johnson, and I. Zineh The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) Am Heart J 157 2009 548 555
21. A.D. Karelis, S.M. Pasternyk, and L. Messier Relationship between insulin sensitivity and the triglyceride-HDL-C ratio in overweight and obese postmenopausal women: a MONET study Appl Physiol Nutr Metab 32 2007 1089 1096
22. M. Ravid, D. Brosh, and D. Ravid-Safran Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia Arch Intern Med 158 1998 998 1004 (Pubitemid 28213577)
23. G. Zoppini, G. Targher, and M. Chonchol Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes Nutr Metab Cardiovasc Dis 19 2009 580 586
24. J.C. Ansquer, C. Foucher, and S. Rattier DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493 (Pubitemid 40341327)
25. A.C. Keech, P. Mitchell, and P.A. Summanen FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697 (Pubitemid 350100775)
26. A. Keech, R.J. Simes, and P. Barter FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
27. C. Forsblom, A. Hiukka, and E.S. Leinonen Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: FIELD Helsinki sub-study Diabetes Care 33 2010 215 220
28. S.J. Nicholls, E.M. Tuzcu, and K. Wolski Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study J Am Coll Cardiol 57 2011 153 159
29. M. Dobiásová, J. Frohlich, and M. Sedová Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography J Lipid Res 52 2011 566 571